Navigation Links
Nausea Drug Shows Promise Against Opioid Addiction
Date:2/18/2009

Ondansetron relieves withdrawal symptoms without side effects, early study shows

WEDNESDAY, Feb. 18 (HealthDay News) -- A drug currently used to treat nausea can prevent symptoms of withdrawal from illegal and prescription opioid drugs such as heroin, morphine and codeine, a new study shows.

The Stanford University scientists behind the research added it can do so without some of the serious side effects caused by existing treatments for addiction to these drugs.

Initial tests in mice showed that the drug ondansetron (Zofran) blocks certain 5-HT3 receptors involved in withdrawal symptoms, the researchers said. They then tested it in eight healthy, non-opioid-dependent volunteers who were given two doses of morphine, once without ondansetron and one with it, and found ondansetron reduced withdrawal symptoms in humans.

The study appears in the Feb. 17 online issue of the Journal of Pharmacogenetics and Genomics.

"Opioid abuse is rising at a faster rate than any other type of illicit drug use, yet only about a quarter of those dependent on opioids seek treatment. One barrier to treatment is that when you abruptly stop taking the drugs, there is a constellation of symptoms associated with withdrawal," lead author Dr. Larry F. Chu, an assistant professor of anesthesia, said in a Stanford news release.

Those symptoms include agitation, insomnia, diarrhea, nausea and vomiting. Current methods of treating withdrawal symptoms aren't completely effective or cause severe side effects, requiring constant patient supervision.

"What we need is a magic bullet, something that treats the symptoms of withdrawal, does not lead to addiction and can be taken at home," Chu added.

The Stanford team plans to continue testing the effectiveness of ondansetron in treating opioid addiction and to conduct a clinical study to determine the effectiveness of an ondansetron-like drug in treating opioid addiction.

However, the researchers noted that ondansetron alone can't solve the problems caused by opioid addiction, which is a long-term, complex process that involves both physical and psychological factors.

"This is not a cure for addiction. It's naive to think that any one receptor is a panacea for treatment. Treating the withdrawal component is only one way of alleviating the suffering. With luck and determination, we can identify additional targets and put together a comprehensive treatment program," principal investigator Dr. J. David Clark, a professor of anesthesia, said in the news release.

More information

The National Institutes of Health has more about opiate withdrawal.



-- Robert Preidt



SOURCE: Stanford University, news release, Feb. 17, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Oncologists Rank Aloxis Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market
2. SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available
3. FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting
4. Explaining chemotherapy-associated nausea
5. Mayo Clinic study finds FDA warning against antinausea drug droperidol unnecessary
6. Acupuncture does not reduce radiotherapy-induced nausea, but patients believe it does
7. No Link Between Anti-Nausea Drug, Heart Trouble
8. HotHead Technologies Heat Sensor Shows Exciting Potential by Kennesaw State University Researchers
9. Partnership for Prevention: CDC Report Shows Compelling Need for FDA Regulation of Tobacco
10. New CDC Study Shows Tobacco Marketing Influences Kids to Smoke, Underscores Need for FDA Regulation of Tobacco Products
11. Caregivers not receiving the help they need, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nausea Drug Shows Promise Against Opioid Addiction
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology: